REGENXBIO shares fell 25% in the premarket as the US FDA suspended the company's clinical trial of gene therapy for Hunter syndrome.

Zhitongcaijing · 2d ago
REGENXBIO shares fell 25% in the premarket as the US FDA suspended the company's clinical trial of gene therapy for Hunter syndrome.